Mersana Therapeutics is a company.
Mersana Therapeutics has raised $110.0M across 4 funding rounds.
Key people at Mersana Therapeutics.
Mersana Therapeutics has raised $110.0M in total across 4 funding rounds.
Mersana Therapeutics has raised $110.0M in total across 4 funding rounds.
Mersana Therapeutics's investors include Avoro Ventures, OrbiMed, Versant Ventures, Elliott Sigal, David Parkinson.
Key people at Mersana Therapeutics.
Mersana Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs) to treat cancer.[1][2][3] It builds proprietary platforms like Dolasynthen (cytotoxic payloads) and Immunosynthen (immunostimulatory payloads) to create customized ADCs targeting cancers such as those expressing B7-H4 or HER2, with a clinical pipeline including Emi-Le (XMT-1660) and XMT-2056.[1][2] The company serves cancer patients by addressing unmet needs through improved efficacy and tolerability over first-generation ADCs, driven by a mission to discover life-changing treatments and a vision of a world where all patients triumph over cancer.[1][2]
Recent growth momentum includes a pivotal acquisition announcement on November 13, 2025, by Day One Biopharmaceuticals, signaling validation of its pipeline and platforms amid ongoing clinical development.[2]
Founded as a biotech innovator in the ADC space, Mersana Therapeutics emerged to tackle limitations in early cancer therapies by pioneering customizable payload platforms.[1][2] While specific founder details are not detailed in available sources, the company built early traction through its Dolasynthen and Immunosynthen technologies, generating a pipeline of wholly-owned and partnered candidates.[1] Key pivotal moments include advancing clinical-stage assets like XMT-1660 and XMT-2056, culminating in the November 2025 acquisition by Day One Biopharmaceuticals, which marks a major milestone in its evolution from independent developer to integrated player in oncology.[2]
Mersana rides the surging wave of ADC technologies in oncology, a trend fueled by demand for precise, potent cancer treatments amid rising cancer incidence and limitations of traditional chemotherapy.[1][2] Timing aligns with maturing ADC ecosystems, where next-generation platforms like Mersana's address payload instability and off-target toxicity, benefiting from market forces like increased biotech M&A—exemplified by its 2025 acquisition.[2] It influences the ecosystem by advancing customizable ADCs, potentially accelerating partner programs and contributing to a shift toward multimodal cancer immunotherapies.
Post-acquisition by Day One Biopharmaceuticals, Mersana's platforms and pipeline will likely integrate into expanded oncology efforts, accelerating clinical readouts for XMT-1660 and XMT-2056.[2] Trends like AI-optimized payloads and combination therapies will shape its trajectory, evolving its influence from standalone innovator to key asset in a larger biotech portfolio driving cancer breakthroughs—ultimately advancing the mission for patients waiting on new options.[1][2]
Mersana Therapeutics has raised $110.0M across 4 funding rounds. Most recently, it raised $33.0M Series C in June 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2016 | $33.0M Series C | Avoro Ventures, OrbiMed, Versant Ventures, Elliott Sigal | |
| Mar 1, 2015 | $35.0M Series B | Avoro Ventures, OrbiMed, Versant Ventures, David Parkinson, Elliott Sigal | |
| Apr 1, 2014 | $15.0M Series A | Avoro Ventures, OrbiMed, Versant Ventures, Elliott Sigal | |
| Jul 1, 2012 | $27.0M Series A | Avoro Ventures, OrbiMed, Versant Ventures, Elliott Sigal |
